Literature DB >> 9168977

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

E Tsuda1, M Goto, S Mochizuki, K Yano, F Kobayashi, T Morinaga, K Higashio.   

Abstract

A factor which inhibits osteoclast-like cell formation was found in the conditioned medium of human embryonic lung fibroblasts, IMR-90. The factor, termed osteoclastogenesis inhibitory factor, OCIF, was purified to homogeneity. OCIF is a heparin-binding basic glycoprotein and has been isolated as a monomer with an apparent molecular weight (Mr) of 60,000 and a homodimer with a Mr of 120,000. The N-terminus of OCIF is blocked and the determination of internal amino acid sequences revealed that OCIF has no homology to known proteins. OCIF inhibited in a dose-dependent manner osteoclastogenesis elicited through three distinct signaling pathways stimulated by 1 alpha,25-dihydroxy vitamin D3, parathyroid hormone, and interleukin-11, respectively, in a dose range of 1 to 40 ng/ml (IC50 = 4 to 6 ng/ml). OCIF neither inhibits bone resorption by mature osteoclasts nor exerts any other biological activities. These data strongly suggest that OCIF is a novel cytokine which specifically inhibits osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9168977     DOI: 10.1006/bbrc.1997.6603

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  135 in total

Review 1.  Hypercalcemia of malignancy.

Authors:  V Grill; T J Martin
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 3.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

4.  Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats.

Authors:  Yoshihiro Miyaji; Yuji Kasuya; Yoshitake Furuta; Atsushi Kurihara; Masayuki Takahashi; Ken-Ichi Ogawara; Takashi Izumi; Osamu Okazaki; Kazutaka Higaki
Journal:  Pharm Res       Date:  2012-06-23       Impact factor: 4.200

5.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

Authors:  L Huang; J Xu; D J Wood; M H Zheng
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

6.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Authors:  C Van Poznak; S S Cross; M Saggese; C Hudis; K S Panageas; L Norton; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 7.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

8.  CSF-1 regulation of osteoclastogenesis for tooth eruption.

Authors:  G E Wise; S Yao; P R Odgren; F Pan
Journal:  J Dent Res       Date:  2005-09       Impact factor: 6.116

9.  Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis.

Authors:  Miaomiao Li; Shuying Yang; Ding Xu
Journal:  J Biol Chem       Date:  2016-10-03       Impact factor: 5.157

Review 10.  Perspectives on osteoporosis in pediatric inflammatory bowel disease.

Authors:  Manisha Harpavat; David J Keljo
Journal:  Curr Gastroenterol Rep       Date:  2003-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.